Plain-English translation of NCT06622798 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying how a genetic test—called an HRD score—can predict which ovarian cancer patients will respond best to a maintenance medication called PARP inhibitors (PARPi) after chemotherapy. This is a retrospective study, meaning researchers will review medical records and test results from about 470 Chinese patients who have already received this treatment. The goal is to establish clear, standardized ways to measure this genetic score so doctors can better decide which patients should receive this medication.
Ovarian cancer often comes back after initial treatment, even when patients respond well at first. While this medication has shown promise in extending the time before cancer returns, doctors don't yet have consistent standards for testing the genetic markers that predict who will benefit most. This study aims to fill that gap by looking at real patient outcomes and establishing reliable guidelines for Chinese patients.
You likely qualify if…
You likely don't qualify if…
As this is a retrospective study, you would not need to visit the hospital repeatedly or take any new medications. Researchers would review your existing medical records, previous test results, and tissue or blood samples already collected during your treatment, typically from 2018 to 2024. Your genetic material would be tested using a specific scoring method to measure DNA repair deficiency, and this score would be compared with how well your cancer responded to the medication you already received.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China